Skip to content
You are now leaving to visit

AKCEA-APO(a)-LRx advances as leading pharmaceutical company exercises option to license

Phase 3 planning and initiation activities underway Akcea earns $150M license fee BOSTON and CARLSBAD, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that